Filtered By:
Drug: Diovan

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
Conclusions In the high CV risk, hypertensives of the VALUE trial reducing BP consistently to <140/90 mmHg had marked beneficial effects both when data were calculated as proportion of visits at BP target or as on-treatment mean BP. Reducing BP to <130/80 mmHg led only to some possible further benefit on stroke, whereas the risk of other outcomes remained substantially similar to or slightly greater than that seen at the higher target. Thus, aggressive BP reductions when CV risk is high may not offer substantial advantages, except perhaps in patients or conditions in which stroke risk is particularly common.
Source: European Heart Journal - March 21, 2016 Category: Cardiology Authors: Mancia, G., Kjeldsen, S. E., Zappe, D. H., Holzhauer, B., Hua, T. A., Zanchetti, A., Julius, S., Weber, M. A. Tags: Hypertension Source Type: research

Effects of Valsartan Versus Amlodipine in Diabetic Hypertensive Patients With or Without Previous Cardiovascular Disease
In conclusion, the ARB- and the CCB-based treatments exerted similar protective effects of CVD events regardless of the presence of previous CVD. For stroke events, the ARB may have more protective effects than the CCB in diabetic hypertensive patients with previous CVD.
Source: The American Journal of Cardiology - September 16, 2013 Category: Cardiology Authors: Kentaro Yamashita, Takahisa Kondo, Takashi Muramatsu, Kunihiro Matsushita, Takanori Nagahiro, Kengo Maeda, Satoshi Shintani, Toyoaki Murohara Tags: Systemic Hypertension Source Type: research

Walking reduces heart disease in people at risk
Conclusion This study of adults at high risk of type 2 diabetes and heart disease has found that every 2,000 steps they normally took each day was associated with a 10% lower risk of a cardiovascular event. And 12 months later, each extra 2,000 steps per day people did beyond their original number of steps was associated with an additional 8% difference in the cardiovascular event rate. This large study recruited participants from around the world and the researchers adjusted for a number of potential confounders. However, the study had a number of limitations, including: A large amount of information on the number of s...
Source: NHS News Feed - December 23, 2013 Category: Consumer Health News Tags: Lifestyle/exercise Source Type: news

Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research

Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
We examined each outcome individually in secondary analyses, in addition to all-cause mortality. RESULTS:We identified 54 186 patients with diabetes who started taking an angiotensinreceptor blocker during the study period. After multivariable adjustment, patients who took either telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74-0.97) or valsartan (adjusted HR 0.86, 95% CI 0.77-0.95) had a lower risk of the composite outcome compared with patients who took irbesartan. In contrast, no significant difference in risk was seen between other angiotensin-receptor blockers and irbesartan. In secondar...
Source: cmaj - July 8, 2013 Category: Journals (General) Authors: Antoniou T, Camacho X, Yao Z, Gomes T, Juurlink DN, Mamdani MM Tags: CMAJ Source Type: research

Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage.
Abstract Angiotensin II receptor blockers (ARBs) are known to prevent ischemic brain damage after stroke. Natriuretic peptides, which are increased by a neprilysin inhibitor, are also reported to protect against brain damage. Therefore, we investigated the possible protective effect of valsartan (VAL) compared with LCZ696 (VAL+ neprilysin inhibitor; 1:1) after middle cerebral artery (MCA) occlusion. Eight-week-old male C57BL/6J mice were treated with VAL (3mg/kg per day) or LCZ696 (6mg/kg per day) for 2 weeks before MCA occlusion. Blood pressure and heart rate were measured by telemetry. Cerebral blood flow (CBF) ...
Source: European Journal of Pharmacology - June 6, 2015 Category: Drugs & Pharmacology Authors: Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Chisaka T, Wang XL, Kukida M, Shan BS, Yamauchi T, Higaki A, Iwanami J, Horiuchi M Tags: Eur J Pharmacol Source Type: research

Treatment of hypertension for low-risk patients questioned
Study funds little evidence of benefits from treatment Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Avoid BP-lowering drugs in stroke Adding insulin to metformin linked to higher mortality Stroke rate higher in HIV patients Recurrent stroke more likely at very low BP
Source: OnMedica Latest News - November 1, 2018 Category: UK Health Source Type: news

Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | DOI:10.3346/jkms.2023.38.e202
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research